SGLT2 inhibitor use as an adjunct-to-insulin therapy in patients with T1D has been limited due to the risk of DKA. Patient input is critical to understand how and when the use of these therapies is perceived to be acceptable. We hypothesize that many patients will prefer to take SGLT2 inhibitors even with some modest increase in the risk of DKA. To test this hypothesis we will use a discrete-choice experiment (DCE) to quantify preference towards treatment options.